Enliven Therapeutics, Inc. (ELVN) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Boulder, CO, 미국. 현재 CEO는 Richard A. Fair.
ELVN 을(를) 보유 IPO 날짜 2020-03-12, 62 명의 정규직 직원, 에 상장 NASDAQ Global Select, 시가총액 $2.63B.
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
